An integrated approach for prospectively investigating a mode-of-action for rodent liver effects

Toxicology and Applied Pharmacology

Volumn 270, Issue 2, 2013, Pages 164-173

  LeBaron, Matthew J ^a   Geter, David R ^a   Rasoulpour, Reza J ^a   Gollapudi, B Bhaskar ^a   Thomas, Johnson ^a   Murray, Jennifer ^a   Kan, H Lynn ^a   Wood, Amanda J ^a   Elcombe, Cliff ^b   Vardy, Audrey ^b   McEwan, Jillian ^b   Terry, Claire ^c   Billington, Richard ^c  

^a DOW CHEMICAL COMPANY   (United States)

^b CXR Biosciences Ltd   (United Kingdom)

^c Dow Agrosciences   (United Kingdom)

Author keywords

CAR PXR; Constitutive androstane receptor; Hepatocellular proliferation; Pesticide

Indexed keywords

CONSTITUTIVE ANDROSTANE RECEPTOR; HERBICIDE; PREGNANE X RECEPTOR; SULFOXAFLOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOASSAY; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HAZARD RATIO; IN VITRO STUDY; IN VIVO STUDY; LIVER; LIVER CARCINOGENESIS; LIVER CELL; LIVER HYPERTROPHY; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; PRACTICE GUIDELINE; RAT; RISK ASSESSMENT; RODENT; STANDARD; TOXICITY TESTING; TUMOR XENOGRAFT;

ANIMALS; CELL PROLIFERATION; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2B1; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INSECTICIDES; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; MICE, KNOCKOUT; MICROSOMES, LIVER; PROSPECTIVE STUDIES; PYRIDINES; RATS; RATS, INBRED F344; REAL-TIME POLYMERASE CHAIN REACTION; RNA; SULFUR COMPOUNDS; TOXICITY TESTS;

EID: 84878257742     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.04.009     Document Type: Article

References (32)

1. Allen D.G., Pearse G., Haseman J.K., Maronpot R.R. Prediction of rodent carcinogenesis: an evaluation of prechronic liver lesions as forecasters of liver tumors in NTP carcinogenicity studies. Toxicol. Pathol. 2004, 32:393-401.
2. Baldwin S.J., Bramhall J.L., Ashby C.A., Yue L., Murdock P.R., Hood S.R., Ayrton A.D., Clarke S.E. Cytochrome P450 gene induction in rats ex vivo assessed by quantitative real-time reverse transcriptase-polymerase chain reaction (TaqMan). Drug Metab. Dispos. 2006, 34:1063-1069.
3. Boobis A.R., Doe J.E., Heinrich-Hirsch B., Meek M.E., Munn S., Ruchirawat M., Schlatter J., Seed J., Vickers C. IPCS framework for analyzing the relevance of a noncancer mode of action for humans. Crit. Rev. Toxicol. 2008, 38:87-96.
4. Boverhof D.R., Burgoon L.D., Tashiro C., Sharratt B., Chittim B., Harkema J.R., Mendrick D.L., Zacharewski T.R. Comparative toxicogenomic analysis of the hepatotoxic effects of TCDD in Sprague Dawley rats and C57BL/6 mice. Toxicol. Sci. 2006, 94:398-416.
5. Burke M.D., Mayer R.T. Differential effects of phenobarbitone and 3-methylcholanthrene induction on the hepatic microsomal metabolism and cytochrome P-450-binding of phenoxazone and a homologous series of its n-alkyl ethers (alkoxyresorufins). Chem. Biol. Interact. 1983, 45:243-258.
6. Cohen S.M. Human carcinogenic risk evaluation: an alternative approach to the two-year rodent bioassay. Toxicol. Sci. 2004, 80:225-229.
7. Cohen S.M. Evaluation of possible carcinogenic risk to humans based on liver tumors in rodent assays: the two-year bioassay is no longer necessary. Toxicol. Pathol. 2010, 38:487-501.
8. Corcos L., Marc N., Wein S., Fautrel A., Guillouzo A., Pineau T. Phenobarbital induces cytochrome P4501A2 hnRNA, mRNA and protein in the liver of C57BL/6J wild type and aryl hydrocarbon receptor knock-out mice. FEBS Lett. 1998, 425:293-297.
9. Dellarco V., Henry T., Sayre P., Seed J., Bradbury S. Meeting the common needs of a more effective and efficient testing and assessment paradigm for chemical risk management. J. Toxicol. Environ. Health B. Crit. Rev. 2010, 13:347-360.
10. Eldridge S.R., Tilbury L.F., Goldsworthy T.L., Butterworth B.E. Measurement of chemically induced cell proliferation in rodent liver and kidney: a comparison of 5-bromo-2'-deoxyuridine and [3H]thymidine administered by injection or osmotic pump. Carcinogenesis 1990, 11:2245-2251.
11. Fletcher N., Wahlstrom D., Lundberg R., Nilsson C.B., Nilsson K.C., Stockling K., Hellmold H., Hakansson H. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) alters the mRNA expression of critical genes associated with cholesterol metabolism, bile acid biosynthesis, and bile transport in rat liver: a microarray study. Toxicol. Appl. Pharmacol. 2005, 207:1-24.
12. Gold L.S., Manley N.B., Slone T.H., Rohrbach L. Supplement to the Carcinogenic Potency Database (CPDB): results of animal bioassays published in the general literature in 1993 to 1994 and by the National Toxicology Program in 1995 to 1996. Environ. Health Perspect. 1999, 107(Suppl. 4):527-600.
13. Gold L.S., Manley N.B., Slone T.H., Rohrbach L., Garfinkel G.B. Supplement to the Carcinogenic Potency Database (CPDB): results of animal bioassays published in the general literature through 1997 and by the National Toxicology Program in 1997-1998. Toxicol. Sci. 2005, 85:747-808.
14. Guengerich F.P. Microsomal enzymes involved in toxicology-analysis and separation. Principles and Methods of Toxiocology 1982, 609-634. Raven Press, New York.
15. Guengerich F.P. Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Res. 1988, 48:2946-2954.
16. Holsapple M.P., Pitot H.C., Cohen S.M., Boobis A.R., Klaunig J.E., Pastoor T., Dellarco V.L., Dragan Y.P. Mode of action in relevance of rodent liver tumors to human cancer risk. Toxicol. Sci. 2006, 89:51-56.
17. Iatropoulos M.J., Williams G.M. Proliferation markers. Exp. Toxicol. Pathol. 1996, 48:175-181.
18. Kennedy S.W., Jones S.P. Simultaneous measurement of cytochrome P4501A catalytic activity and total protein concentration with a fluorescence plate reader. Anal. Biochem. 1994, 222:217-223.
19. Kiupel M., Teske E., Bostock D. Prognostic factors for treated canine malignant lymphoma. Vet. Pathol. 1999, 36:292-300.
20. Lake B.G. Species differences in the hepatic effects of inducers of CYP2B and CYP4A subfamily forms: relationship to rodent liver tumour formation. Xenobiotica 2009, 39:582-596.
21. Lubet R.A., Mayer R.T., Cameron J.W., Nims R.W., Burke M.D., Wolff T., Guengerich F.P. Dealkylation of pentoxyresorufin: a rapid and sensitive assay for measuring induction of cytochrome(s) P-450 by phenobarbital and other xenobiotics in the rat. Arch. Biochem. Biophys. 1985, 238:43-48.
22. Maronpot R.R., Yoshizawa K., Nyska A., Harada T., Flake G., Mueller G., Singh B., Ward J.M. Hepatic enzyme induction: histopathology. Toxicol Pathol 2010, 38:776-795.
23. Meek M.E., Bucher J.R., Cohen S.M., Dellarco V., Hill R.N., Lehman-McKeeman L.D., Longfellow D.G., Pastoor T., Seed J., Patton D.E. A framework for human relevance analysis of information on carcinogenic modes of action. Crit. Rev. Toxicol. 2003, 33:591-653.
24. Ross J., Plummer S.M., Rode A., Scheer N., Bower C.C., Vogel O., Henderson C.J., Wolf C.R., Elcombe C.R. Human constitutive androstane receptor (CAR) and pregnane X receptor (PXR) support the hypertrophic but not the hyperplastic response to the murine nongenotoxic hepatocarcinogens phenobarbital and chlordane in vivo. Toxicol. Sci. 2010, 116:452-466.
25. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 2008, 3:1101-1108.
26. Sistare F.D., Morton D., Alden C., Christensen J., Keller D., Jonghe S.D., Storer R.D., Reddy M.V., Kraynak A., Trela B., Bienvenu J.G., Bjurstrom S., Bosmans V., Brewster D., Colman K., Dominick M., Evans J., Hailey J.R., Kinter L., Liu M., Mahrt C., Marien D., Myer J., Perry R., Potenta D., Roth A., Sherratt P., Singer T., Slim R., Soper K., Fransson-Steen R., Stoltz J., Turner O., Turnquist S., van Heerden M., Woicke J., DeGeorge J.J. An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines. Toxicol. Pathol. 2011, 39:716-744.
27. Sonich-Mullin C., Fielder R., Wiltse J., Baetcke K., Dempsey J., Fenner-Crisp P., Grant D., Hartley M., Knaap A., Kroese D., Mangelsdorf I., Meek E., Rice J.M., Younes M. IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Regul. Toxicol. Pharmacol. 2001, 34:146-152.
28. Steel R.G.D., Torrie J.H. Principles and Procedures of Statistics 1960, McGraw-Hill, New York.
29. Wei P., Zhang J., Egan-Hafley M., Liang S., Moore D.D. The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature 2000, 407:920-923.
30. Williams G.M., Whysner J. Epigenetic carcinogens: evaluation and risk assessment. Exp. Toxicol. Pathol. 1996, 48:189-195.
31. Winer B.J. Statistical Principles in Experimental Design 1971, McGraw-Hill, New York.
32. Yamamoto Y., Moore R., Goldsworthy T.L., Negishi M., Maronpot R.R. The orphan nuclear receptor constitutive active/androstane receptor is essential for liver tumor promotion by phenobarbital in mice. Cancer Res. 2004, 64:7197-7200.